Developer docs
API playgroundTry for free, no card

Search company profiles

Standigm

Full company profile

uuid0000oxt

Namestring
Standigm
Legal namestring
주식회사 스탠다임 (Standigm Inc.)
Websiteurl
standigm.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Standigm is a Seoul-headquartered AI drug discovery company founded in May 2015 that builds end-to-end platforms spanning novel target identification, compound design, and lead optimization for pharmaceutical and biotechnology clients. Its core architecture combines a biology platform (Standigm ASK, powered by a knowledge graph covering 70K+ nodes and 4M+ edges drawn from 36 public databases and 97K scientific publications) with a chemistry platform (Standigm BEST, integrating proprietary algorithms ChemMap, GPN, Monet, NoSH, and IDEA-STAR) and an integrated workflow layer (Standigm Magic). Standigm also maintains proprietary therapeutic programs across cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia), and in 2023 opened an in-house synthesis lab to close the design-make-test loop.

The company monetizes through three streams: (1) AI SaaS and API platform subscriptions for STELLA, SPICA, QIP-ADMET, GT-AutoML, and ASK-LLM, distributed via a self-serve model with a 2-week free trial; (2) collaborative research services with pharmaceutical partners; and (3) long-tail licensing and out-licensing economics from its proprietary pipeline. Its customer base is anchored by Korean pharma majors (SK chemicals, Hanmi Pharmaceutical, HK inno.N, Samjin Pharmaceuticals) and a growing set of global research institutions (Milner Therapeutics Institute, Institut Pasteur Korea, KIST, Ewha Womans University, Ajou University Hospital). Go-to-market combines direct enterprise sales for pharma collaborations, product-led growth via SaaS, channel partnerships, and event-driven engagement (notably BIO Korea).

Standigm has raised $71.2M total across seed (2015, $280K), Series A (2016, ~$3M), Series B (2019, $11.6M) with SK Holdings strategic capital ($7.2M), and Series C (2021-2023, $46.4M) including Pavilion Capital ($10M, 2021) and SK Chemicals ($2.7M). It employs 51-100 people across Seoul, UK, and US offices, has been recognized by Gartner (Tech Innovator 2023), Forbes Korea (AI 50 2024), and Fast Company (World Changing Ideas 2022), and positions itself against larger tech entrants as a workflow-AI specialist.

Short descriptiontext

Standigm is a Seoul-based AI drug discovery company offering end-to-end workflow AI platforms for novel target identification, compound design, and lead optimization, serving global pharmaceutical companies, biotech firms, and research institutions through SaaS, APIs, and collaborative research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, drug target identification, compound design, drug repurposing, AI SaaS platform
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Software
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI SaaS & API Platform Services
TypeSubscription Recurring
Description

Standigm generates revenue by offering AI platform services through cloud-based SaaS and API products including STELLA, QIP-ADMET, SPICA, GT-AutoML, and ASK-LLM. Customers pay for platform access to accelerate their drug discovery processes. The company offers free trials to drive adoption with conversion to paid subscriptions.

standigm.com
2Proprietary Drug Pipeline Development
TypeLicensing Royalties
Description

Standigm develops its own therapeutic asset pipeline through in-house and collaborative research projects targeting cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia). Revenue is generated through out-licensing of candidates or commercial partnerships.

standigm.com
3Collaborative Research Services
TypeProfessional Services
Description

Standigm provides AI-driven drug discovery services to pharmaceutical partners under collaborative research agreements. Partners include SK chemicals, Hanmi Pharmaceutical, HK inno.N, and others. Services include novel target identification, hit-to-lead optimization, and workflow AI integration.

standigm.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Free Trial - 2 Weeks, 1,000 Molecule Ideas
ModelFreemiumBilling cadencePay-as-you-go
Notes

Standigm offers a free trial providing 1,000 new molecule ideas for customer's target within 1 week. Trial period is 2 weeks with no commitments or hidden limits. Limited to 20 spots.

standigm.com
2AI SaaS Platform Access
ModelSubscriptionBilling cadenceAnnual
Notes

Full platform access to STELLA, QIP-ADMET, SPICA, GT-AutoML, and ASK-LLM requires subscription. Pricing not publicly disclosed; contact-based quoting.

standigm.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1ASK™
Description

AI-aided novel target identification platform for customized drug target discovery.

standigm.com
+7 more records
Core offering1 text field

Standigm builds and sells an end-to-end AI-driven drug discovery platform that combines a biology platform for novel drug target identification with a chemistry platform for designing and optimizing drug molecules. Its SaaS/API products (STELLA, SPICA, QIP-ADMET, GT-AutoML, ASK-LLM) and core platforms (Standigm ASK, BEST, Magic) are sold to pharmaceutical companies, biotech firms, and research institutions to accelerate drug discovery and reduce development timelines. The company also generates revenue through collaborative research services with pharmaceutical partners and proprietary drug pipeline development for out-licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced material optimization timeline from industry average of 4.5 years to 1.5 years (67% reduction)
+2 more records
Product overview1 text field

Standigm is an AI drug discovery company offering an integrated platform architecture combining biology and chemistry platforms. The product portfolio includes Standigm ASK for novel target identification, Standigm BEST for compound design and hit-to-lead optimization, Standigm Magic for integrated workflow AI, and Standigm Expander/Insight for drug repurposing. The AI SaaS suite includes STELLA (MPO platform), SPICA (novelty assessment), QIP-ADMET (ADMET prediction), GT-AutoML (automated QSAR modeling), and ASK-LLM (knowledge graph-to-text generation). Standigm provides end-to-end solutions ranging from discovery to active material exploration, optimization, and derivation of preclinical candidate materials, reportedly reducing material optimization from 4.5 years to 1.5 years.

Product and service10 records
1Standigm ASK
CategoryCore Platform
Description

AI-aided drug target identification platform providing comprehensive database integration from literature and public databases, customizable machine learning approaches for novel target insights, and an interactive user interface for target-disease relationship analysis. Built on Standigm BioMap knowledge graph with 30K targets, 10K phenotypes, 5K drugs, 4.3M relations, 36 databases, and 97K publications.

2Standigm BEST
CategoryCore Platform
Description

Comprehensive compound design platform comprising multiple drug design AI modules including ChemMap (deep learned chemical space), GPN (Graph Point Network for 2D/3D structural information), Monet (moiety-based molecular networks for derivative enumeration), NoSH (novel scaffold hopping), and IDEA-STAR (virtual screening combining multi-pose docking and active learning). Addresses all scenarios from hit identification to lead optimization.

3STELLA
CategoryAI SaaS
Description

Innovative MPO (Multi-Parameter Optimization) platform for hit-to-lead optimization, powered by genetic algorithms and advanced AI. Accelerates drug candidate creation and refinement from concept to market-ready molecular design with multi-objective optimization capabilities. Sold as cloud-based AI SaaS.

4SPICA
CategoryAI SaaS
Description

AI-based patentability prediction model that swiftly computes novelty prospects for new molecular structures born from AI synthesis. Delivers rapid, precise novelty evaluations ensuring a clear path toward patent protection. Sold as cloud-based AI SaaS.

5QIP-ADMET
CategoryAI SaaS
Description

Quantum-Informed Pretrained ADMET prediction models trained on extensive datasets including experimental data, in silico quantum mechanical (QM) data, and molecular descriptors. Delivers swift and reliable predictions for Absorption, Distribution, Metabolism, Excretion, and Toxicity to propel candidates toward clinical success. Sold as cloud-based AI SaaS.

6GT-AutoML
CategoryAI SaaS
Description

Automated QSAR modeling platform supporting both ligand-based and structure-based approaches. Automates labor-intensive steps such as ligand alignment and integrates multi-level molecular descriptors from state-of-the-art foundation models. Sold as cloud-based AI SaaS.

7ASK-LLM
CategoryAI SaaS
Description

Retrieval Augmented Generation (RAG) system that transforms knowledge graphs into actionable text insights. Advanced hypothesis-generating assistant that guides researchers to faster, more reliable conclusions with contextually curated references and streamlined summaries. Sold as cloud-based AI SaaS.

8Standigm Magic
CategoryCore Platform
Description

Integration of Workflow AI from target identification to lead optimization, enabling end-to-end automated drug discovery workflows.

9Standigm Expander
CategoryCore Platform
Description

Drug repurposing platform for identifying novel indications for existing compounds.

10Standigm Insight
CategoryCore Platform
Description

Enhanced drug repurposing platform for improved target-disease relationship analysis.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1SK chemicals
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Major pharmaceutical partnership with SK chemicals for automated workflow AI technology collaboration. SK chemicals uses Standigm's AI to continuously develop optimal drug candidates in shorter periods and lower cost than traditional methodologies. Both companies report remarkable research results from the collaboration.

standigm.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic partnership with Hanmi Pharmaceutical, one of Korea's largest pharmaceutical companies, for AI-driven drug discovery collaboration.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Partnership with HK inno.N for AI-powered drug discovery services and collaborative research.

4Samjin Pharmaceuticals Co., Ltd.
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Collaboration with Samjin Pharmaceuticals using Standigm's AI technology to produce drug candidates with drug-patentability by maintaining physicochemical properties and modifying structures.

standigm.com
5SK Inc. C&C
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Partnership with SK Inc. C&C as a leading digital transformation company to establish an ecosystem for new AI drug discovery platforms in the global pharmaceutical & bio market.

standigm.com
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Partnership with Milner Therapeutics Institute at University of Cambridge for global research collaboration in AI-driven drug discovery.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Academic partnership with Ewha Womans University for customized target discovery research using Standigm's AI technology to extract important information from vast databases while integrating specific research context and private data.

8Institut Pasteur Korea
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Research collaboration with Institut Pasteur Korea for discovering active anti-tubercular compounds using Standigm's AI approach based on previous HTS assay results with Mycobacterium tuberculosis.

standigm.com
9Ajou University Hospital
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Partnership with Ajou University Hospital using Standigm Insight platform for rational drug repurposing, successfully finding existing drugs showing efficacy for intractable diseases without laborious high-throughput phenotypic screening.

standigm.com
Strategic tierKeyTypeStrategic or Co-development Partner
Description

Research partnership with KIST for collaborative AI-driven drug discovery projects.

Strategic tierStandardTypeStrategic or Co-development Partner
Description

Listed partnership with LigaChem Biosciences for potential collaborative research in drug discovery.

Strategic tierStandardTypeStrategic or Co-development Partner
Description

Listed partnership with Curome Biosciences for potential collaborative research.

Strategic tierStandardTypeStrategic or Co-development Partner
Description

Partnership with Cure Mito Foundation for research in mitochondrial diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insilico Medicine is a leading AI-driven drug discovery company with end-to-end target identification, generative chemistry, and clinical-stage pipeline (e.g., INS018_055 in IPF). Directly comparable to Standigm's AI drug discovery platform across target ID, hit-to-lead, and proprietary pipeline, though larger and more advanced.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Operates a platform-plus-pipeline model similar to Standigm, with partnerships (Roche, Genentech, Bayer) and proprietary pipeline programs.

TypeDirect peer
Description

Schrödinger provides computational chemistry/A SaaS platform (LiveDesign) used by major pharma, alongside an internal pipeline. Closely comparable to Standigm in delivering physics-based and AI drug discovery software plus proprietary programs.

TypeDirect peer
Description

Atomwise applies AI (AtomNet) to small-molecule hit discovery with pharma partnerships. Comparable to Standigm in target identification and compound design, with similar commercial model of pharma collaborations plus proprietary programs.

TypeDirect peer
Description

Exscientia is an AI-driven precision medicine company with end-to-end discovery capabilities and pharma partnerships (e.g., Bristol Myers Squibb). Directly comparable AI drug discovery peer with both platform and pipeline assets.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and robotics for small-molecule drug discovery with global pharma partnerships. Comparable AI+CRO model to Standigm, with larger scale and broader wet-lab integration.

TypeDirect peer
Description

BenevolentAI uses knowledge graphs and AI for drug discovery with programs in neurodegeneration and rare diseases. Comparable to Standigm's knowledge-graph-based target ID approach, with similar AI-platform-plus-pipeline structure.

8Iambic Therapeutics
TypeEmerging player
Description

Iambic develops AI-driven small-molecule discovery platforms (including NeuralPLexer for protein-ligand structure prediction). Overlaps with Standigm's generative chemistry and structure-based design capabilities as an emerging AI-native competitor.

TypeBroad incumbent
Description

Isomorphic Labs (Alphabet/DeepMind) builds on AlphaFold to commercialize AI drug discovery with major pharma partnerships (Eli Lilly, Novartis). A well-capitalized broad incumbent that could outcompete smaller AI platforms like Standigm on scale, data, and brand.

TypeBroad incumbent
Description

NVIDIA provides BioNeMo and Clara platforms for AI-driven drug discovery and life sciences. As an infrastructure incumbent, it competes indirectly with Standigm by enabling pharma to build internal AI capabilities rather than buying from vendors like Standigm.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Standigm

AI Drug Discovery Softwarestandigm.com

Standigm is a Seoul-based AI drug discovery company offering end-to-end workflow AI platforms for novel target identification, compound design, and lead optimization, serving global pharmaceutical companies, biotech firms, and research institutions through SaaS, APIs, and collaborative research.

What Standigm does

Standigm is a Seoul-headquartered AI drug discovery company founded in May 2015 that builds end-to-end platforms spanning novel target identification, compound design, and lead optimization for pharmaceutical and biotechnology clients. Its core architecture combines a biology platform (Standigm ASK, powered by a knowledge graph covering 70K+ nodes and 4M+ edges drawn from 36 public databases and 97K scientific publications) with a chemistry platform (Standigm BEST, integrating proprietary algorithms ChemMap, GPN, Monet, NoSH, and IDEA-STAR) and an integrated workflow layer (Standigm Magic). Standigm also maintains proprietary therapeutic programs across cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia), and in 2023 opened an in-house synthesis lab to close the design-make-test loop.

The company monetizes through three streams: (1) AI SaaS and API platform subscriptions for STELLA, SPICA, QIP-ADMET, GT-AutoML, and ASK-LLM, distributed via a self-serve model with a 2-week free trial; (2) collaborative research services with pharmaceutical partners; and (3) long-tail licensing and out-licensing economics from its proprietary pipeline. Its customer base is anchored by Korean pharma majors (SK chemicals, Hanmi Pharmaceutical, HK inno.N, Samjin Pharmaceuticals) and a growing set of global research institutions (Milner Therapeutics Institute, Institut Pasteur Korea, KIST, Ewha Womans University, Ajou University Hospital). Go-to-market combines direct enterprise sales for pharma collaborations, product-led growth via SaaS, channel partnerships, and event-driven engagement (notably BIO Korea).

Standigm has raised $71.2M total across seed (2015, $280K), Series A (2016, ~$3M), Series B (2019, $11.6M) with SK Holdings strategic capital ($7.2M), and Series C (2021-2023, $46.4M) including Pavilion Capital ($10M, 2021) and SK Chemicals ($2.7M). It employs 51-100 people across Seoul, UK, and US offices, has been recognized by Gartner (Tech Innovator 2023), Forbes Korea (AI 50 2024), and Fast Company (World Changing Ideas 2022), and positions itself against larger tech entrants as a workflow-AI specialist.

Standigm firmographics

Firmographics
Name
Standigm
Legal name
주식회사 스탠다임 (Standigm Inc.)
Website
https://standigm.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Standigm is a Seoul-based AI drug discovery company offering end-to-end workflow AI platforms for novel target identification, compound design, and lead optimization, serving global pharmaceutical companies, biotech firms, and research institutions through SaaS, APIs, and collaborative research.
Ownership category
akta.pro rank

Standigm industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Drug target identification
  • Compound design
  • Drug repurposing
  • AI SaaS platform

Where Standigm is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Standigm business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI SaaS & API Platform Services: Standigm generates revenue by offering AI platform services through cloud-based SaaS and API products including STELLA, QIP-ADMET, SPICA, GT-AutoML, and ASK-LLM. Customers pay for platform access to accelerate their drug discovery processes. The company offers free trials to drive adoption with conversion to paid subscriptions.
  2. Proprietary Drug Pipeline Development: Standigm develops its own therapeutic asset pipeline through in-house and collaborative research projects targeting cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia). Revenue is generated through out-licensing of candidates or commercial partnerships.
  3. Collaborative Research Services: Standigm provides AI-driven drug discovery services to pharmaceutical partners under collaborative research agreements. Partners include SK chemicals, Hanmi Pharmaceutical, HK inno.N, and others. Services include novel target identification, hit-to-lead optimization, and workflow AI integration.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial - 2 Weeks, 1,000 Molecule Ideas
SubscriptionAnnualAI SaaS Platform Access

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Standigm product offering

Product offering

Core offering

Standigm builds and sells an end-to-end AI-driven drug discovery platform that combines a biology platform for novel drug target identification with a chemistry platform for designing and optimizing drug molecules. Its SaaS/API products (STELLA, SPICA, QIP-ADMET, GT-AutoML, ASK-LLM) and core platforms (Standigm ASK, BEST, Magic) are sold to pharmaceutical companies, biotech firms, and research institutions to accelerate drug discovery and reduce development timelines. The company also generates revenue through collaborative research services with pharmaceutical partners and proprietary drug pipeline development for out-licensing.

Product overview

Standigm is an AI drug discovery company offering an integrated platform architecture combining biology and chemistry platforms. The product portfolio includes Standigm ASK for novel target identification, Standigm BEST for compound design and hit-to-lead optimization, Standigm Magic for integrated workflow AI, and Standigm Expander/Insight for drug repurposing. The AI SaaS suite includes STELLA (MPO platform), SPICA (novelty assessment), QIP-ADMET (ADMET prediction), GT-AutoML (automated QSAR modeling), and ASK-LLM (knowledge graph-to-text generation). Standigm provides end-to-end solutions ranging from discovery to active material exploration, optimization, and derivation of preclinical candidate materials, reportedly reducing material optimization from 4.5 years to 1.5 years.

Differentiator

Problem solved

Functional benefit

Brands

  • ASK™: AI-aided novel target identification platform for customized drug target discovery.
  • ASK-LLM™
  • BEST™
  • SPICA™
  • QIP-ADMET™
  • STELLA™
  • GT-AutoML™
  • Standigm GPT

Products and services

  • Standigm ASK AI-aided drug target identification platform providing comprehensive database integration from literature and public databases, customizable machine learning approaches for novel target insights, and an interactive user interface for target-disease relationship analysis. Built on Standigm BioMap knowledge graph with 30K targets, 10K phenotypes, 5K drugs, 4.3M relations, 36 databases, and 97K publications.
  • Standigm BEST Comprehensive compound design platform comprising multiple drug design AI modules including ChemMap (deep learned chemical space), GPN (Graph Point Network for 2D/3D structural information), Monet (moiety-based molecular networks for derivative enumeration), NoSH (novel scaffold hopping), and IDEA-STAR (virtual screening combining multi-pose docking and active learning). Addresses all scenarios from hit identification to lead optimization.
  • STELLA Innovative MPO (Multi-Parameter Optimization) platform for hit-to-lead optimization, powered by genetic algorithms and advanced AI. Accelerates drug candidate creation and refinement from concept to market-ready molecular design with multi-objective optimization capabilities. Sold as cloud-based AI SaaS.
  • SPICA AI-based patentability prediction model that swiftly computes novelty prospects for new molecular structures born from AI synthesis. Delivers rapid, precise novelty evaluations ensuring a clear path toward patent protection. Sold as cloud-based AI SaaS.
  • QIP-ADMET Quantum-Informed Pretrained ADMET prediction models trained on extensive datasets including experimental data, in silico quantum mechanical (QM) data, and molecular descriptors. Delivers swift and reliable predictions for Absorption, Distribution, Metabolism, Excretion, and Toxicity to propel candidates toward clinical success. Sold as cloud-based AI SaaS.
  • GT-AutoML Automated QSAR modeling platform supporting both ligand-based and structure-based approaches. Automates labor-intensive steps such as ligand alignment and integrates multi-level molecular descriptors from state-of-the-art foundation models. Sold as cloud-based AI SaaS.
  • ASK-LLM Retrieval Augmented Generation (RAG) system that transforms knowledge graphs into actionable text insights. Advanced hypothesis-generating assistant that guides researchers to faster, more reliable conclusions with contextually curated references and streamlined summaries. Sold as cloud-based AI SaaS.
  • Standigm Magic Integration of Workflow AI from target identification to lead optimization, enabling end-to-end automated drug discovery workflows.
  • Standigm Expander Drug repurposing platform for identifying novel indications for existing compounds.
  • Standigm Insight Enhanced drug repurposing platform for improved target-disease relationship analysis.

Quantifiable outcome

  • Reduced material optimization timeline from industry average of 4.5 years to 1.5 years (67% reduction)
  • +2 more outcomes

Companies that use Standigm

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Standigm technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature12 records

Standigm partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, key and standard.

  • SK chemicalsflagshipStrategic or Co-development PartnerMajor pharmaceutical partnership with SK chemicals for automated workflow AI technology collaboration. SK chemicals uses Standigm's AI to continuously develop optimal drug candidates in shorter periods and lower cost than traditional methodologies. Both companies report remarkable research results from the collaboration.
  • Hanmi PharmaceuticalflagshipStrategic or Co-development PartnerStrategic partnership with Hanmi Pharmaceutical, one of Korea's largest pharmaceutical companies, for AI-driven drug discovery collaboration.
  • HK inno.NkeyStrategic or Co-development PartnerPartnership with HK inno.N for AI-powered drug discovery services and collaborative research.
  • Samjin Pharmaceuticals Co., Ltd.keyStrategic or Co-development PartnerCollaboration with Samjin Pharmaceuticals using Standigm's AI technology to produce drug candidates with drug-patentability by maintaining physicochemical properties and modifying structures.
  • SK Inc. C&CkeyStrategic or Co-development PartnerPartnership with SK Inc. C&C as a leading digital transformation company to establish an ecosystem for new AI drug discovery platforms in the global pharmaceutical & bio market.
  • Milner Therapeutics InstitutekeyStrategic or Co-development PartnerPartnership with Milner Therapeutics Institute at University of Cambridge for global research collaboration in AI-driven drug discovery.
  • Ewha Womans UniversitykeyStrategic or Co-development PartnerAcademic partnership with Ewha Womans University for customized target discovery research using Standigm's AI technology to extract important information from vast databases while integrating specific research context and private data.
  • Institut Pasteur KoreakeyStrategic or Co-development PartnerResearch collaboration with Institut Pasteur Korea for discovering active anti-tubercular compounds using Standigm's AI approach based on previous HTS assay results with Mycobacterium tuberculosis.
  • Ajou University HospitalkeyStrategic or Co-development PartnerPartnership with Ajou University Hospital using Standigm Insight platform for rational drug repurposing, successfully finding existing drugs showing efficacy for intractable diseases without laborious high-throughput phenotypic screening.
  • Korea Institute of Science and Technology (KIST)keyStrategic or Co-development PartnerResearch partnership with KIST for collaborative AI-driven drug discovery projects.
  • LigaChem Biosciences, Inc. (LCB)standardStrategic or Co-development PartnerListed partnership with LigaChem Biosciences for potential collaborative research in drug discovery.
  • Curome BiosciencesstandardStrategic or Co-development PartnerListed partnership with Curome Biosciences for potential collaborative research.
  • Cure Mito FoundationstandardStrategic or Co-development PartnerPartnership with Cure Mito Foundation for research in mitochondrial diseases.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Standigm competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company with end-to-end target identification, generative chemistry, and clinical-stage pipeline (e.g., INS018_055 in IPF). Directly comparable to Standigm's AI drug discovery platform across target ID, hit-to-lead, and proprietary pipeline, though larger and more advanced.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Operates a platform-plus-pipeline model similar to Standigm, with partnerships (Roche, Genentech, Bayer) and proprietary pipeline programs.
  • Schrödinger, Inc. Schrödinger provides computational chemistry/A SaaS platform (LiveDesign) used by major pharma, alongside an internal pipeline. Closely comparable to Standigm in delivering physics-based and AI drug discovery software plus proprietary programs.
  • Atomwise: Atomwise applies AI (AtomNet) to small-molecule hit discovery with pharma partnerships. Comparable to Standigm in target identification and compound design, with similar commercial model of pharma collaborations plus proprietary programs.
  • Exscientia: Exscientia is an AI-driven precision medicine company with end-to-end discovery capabilities and pharma partnerships (e.g., Bristol Myers Squibb). Directly comparable AI drug discovery peer with both platform and pipeline assets.
  • XtalPi: XtalPi combines AI, quantum physics, and robotics for small-molecule drug discovery with global pharma partnerships. Comparable AI+CRO model to Standigm, with larger scale and broader wet-lab integration.
  • BenevolentAI: BenevolentAI uses knowledge graphs and AI for drug discovery with programs in neurodegeneration and rare diseases. Comparable to Standigm's knowledge-graph-based target ID approach, with similar AI-platform-plus-pipeline structure.

Emerging players

  • Iambic Therapeutics: Iambic develops AI-driven small-molecule discovery platforms (including NeuralPLexer for protein-ligand structure prediction). Overlaps with Standigm's generative chemistry and structure-based design capabilities as an emerging AI-native competitor.

Broad incumbents

  • Google DeepMind (Isomorphic Labs): Isomorphic Labs (Alphabet/DeepMind) builds on AlphaFold to commercialize AI drug discovery with major pharma partnerships (Eli Lilly, Novartis). A well-capitalized broad incumbent that could outcompete smaller AI platforms like Standigm on scale, data, and brand.
  • NVIDIA (BioNeMo / Clara): NVIDIA provides BioNeMo and Clara platforms for AI-driven drug discovery and life sciences. As an infrastructure incumbent, it competes indirectly with Standigm by enabling pharma to build internal AI capabilities rather than buying from vendors like Standigm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Standigm social profiles

Digital presence

Standigm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Standigm leadership team

Management profile

Number of profiles

Profiles7 records

Standigm funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Standigm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Standigm

What does Standigm do?

Standigm builds and sells an end-to-end AI-driven drug discovery platform that combines a biology platform for novel drug target identification with a chemistry platform for designing and optimizing drug molecules. Its SaaS/API products (STELLA, SPICA, QIP-ADMET, GT-AutoML, ASK-LLM) and core platforms (Standigm ASK, BEST, Magic) are sold to pharmaceutical companies, biotech firms, and research institutions to accelerate drug discovery and reduce development timelines. The company also generates revenue through collaborative research services with pharmaceutical partners and proprietary drug pipeline development for out-licensing.

Is Standigm a public or private company?

Standigm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Standigm founded?

Standigm was founded in 2015. It employs 11 to 50 people.

Where is Standigm based?

Standigm is headquartered in Seoul, South Korea, in the Asia region.

How does Standigm make money?

Three revenue lines are on record. AI SaaS & API Platform Services are the primary driver. The others are proprietary Drug Pipeline Development and collaborative Research Services.

Who are Standigm's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Inc., Atomwise, Exscientia, XtalPi and BenevolentAI. Iambic Therapeutics is listed as an emerging player. Broad incumbents are Google DeepMind (Isomorphic Labs) and NVIDIA (BioNeMo / Clara).

Does Standigm have an API?

Yes. Standigm offers AI SaaS and API solutions enabling external access to its AI drug discovery platform services. Products mentioned include STELLA, SPICA, QIP-ADMET, and ASK-LLM available as cloud applications. Trial access available upon request.

What industry is Standigm in?

Standigm's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireStandigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AIStandigm and Protai announced a two-year joint R&D program to design selective molecular glue degraders, supported by KORIL-RDF. The collaboration pairs Protai's AI structural proteomics with Standigm's generative AI to address selectivity, a key challenge in targeted protein degradation.openPR.comAI Drug Development Platform Market CAGR 29.90% Future Outlook Led by Insilico Medicine, MindRank, BenevolentAI, Exscientia, Deep Pharma Intelligence, Delta4, DNDi, StandigmThe AI drug development platform market is projected to grow at a CAGR of 29.90% from 2025 to 2032. Growth is driven by the need for efficient drug discovery, with key players including Insilico Medicine, MindRank, BenevolentAI, and Exscientia. The market is expected to surpass a substantial valuation by 2032.OUPblogStandigm ASK™: knowledge graph and artificial intelligence platform applied to target discovery in idiopathic pulmonary fibrosisStandigm ASK, an AI platform combining a heterogeneous knowledge graph with an attention-based neural network, was applied to identify drug targets for idiopathic pulmonary fibrosis. It ranked AMFR, MDFIC and NR5A2 as top candidates, which were validated in L132 cells where TGFβ treatment induced epithelial–mesenchymal transition and siRNA knockdown reversed these changes.PR NewswireStandigm named as a Tech Innovator in Generative AI in Drug Discovery use caseStandigm, an AI-based drug discovery company, was named a Tech Innovator in Generative AI for Novel Drug Discovery in a Gartner report. The company offers platforms for target identification, compound design, and molecular optimization, and is seeking collaborations with Big Tech firms.PR NewswireStandigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness WeekStandigm, a South Korea-based AI drug discovery company, launched its "Green Ribbon Campaign" on September 5, 2023, to raise awareness for Mitochondrial Disease Awareness Week. The company also announced a Memorandum of Understanding with Curome Biosciences to jointly develop treatments for mitochondrial diseases, leveraging Standigm's AI platform and Curome's rare disease expertise.GreyBTop 10 AI Drug Discovery Startups to Watch in 2025A roundup article profiles ten AI-driven startups advancing drug discovery, including Exscientia, Standigm, Genesis Therapeutics, Data2Discovery, Unlearn.AI and Recursion. It details each company's AI platform, patent counts, funding rounds and collaborations, such as Exscientia's $525m Softbank round and Recursion's $50m NVIDIA deal.PR NewswireStandigm and Nashville Biosciences join to revolutionize early drug discoveryStandigm announced a collaboration with Nashville Biosciences, a Vanderbilt University Medical Center subsidiary, to use its genomic and clinical data for building AI models in early drug discovery. The partnership aims to accelerate target identification and improve patient outcomes. Standigm's AI platforms will integrate the data to surface insights without requiring customers to source proprietary data themselves.PR NewswireStandigm announces Younsung Choo as chief executive officerStandigm appointed Younsung Choo as CEO, a former LG Life Sciences executive and long-time advisor. He will focus on strategy, R&D, and business development, bringing experience including leading Korea's first FDA-approved new drug, Factive. The company plans to expand its AI drug discovery platform under his leadership.PR NewswireStandigm cited as 'Top 10 Generative AI-based startup based on VC Investment, 2019-2021' in Gartner® reportStandigm, a Seoul-based AI drug discovery company, announced it was ranked seventh in Gartner's 2022 report on top generative AI startups by VC investment for the 2019-2021 period. According to Gartner data, global investment in AI-assisted drug discovery surged 180% to $840 million in 2021 from $299 million in 2020, with roughly half of that capital directed at AI-assisted drug discovery startups. Standigm's BEST platform uses proprietary scaffold replacement technology combined with generative AI models to support hit identification, hit-to-lead, and lead optimization stages of early drug discovery.PR NewswireStandigm Synthetic Research Center successfully accelerates drug discovery in its first yearStandigm, a workflow AI-driven drug discovery company, celebrated the first anniversary of its Synthetic Research Center, which enables collaboration between chemical and AI researchers to accelerate drug discovery. The center has synthesized hundreds of novel molecules and significantly reduced timelines: compound generation dropped from 6 months to 2 months, while first go/no-go decisions shortened from 3-4 years to an average of 7 months. Standigm is now using a closed-loop system combining reinforced learning AI algorithms with high-quality experimental data generation to further advance its drug discovery capabilities.